Posted by Michael Wonder on 19 Jul 2026
European Commission approves Erbitux (cetuximab) in combination with encorafenib and FOLFOX for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation
14 July 2026 - Merck today announced that the European Commission approved an update to the Erbitux (cetuximab) EU label on 26 June 2026.
Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E mutant metastatic colorectal cancer — both in first-line treatment in combination with FOLFOX (BREAKWATER regimen) and for patients who have received prior systemic therapy (BEACON regimen).
